8 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Active not recruiting 1, Unknown 1, Withdrawn 1 |
Follow GM-CSF: new trials by email Literature Review of GM-CSF trials Research Report on GM-CSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS GM-CSF, Placebo - Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome | Phase 3 | Completed | Nationwide Children's Hospital | 141 | 2022-06-14 | 2026-04-09 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 Galinpepimut-S, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Sellas Life Sciences Group | 127 | 2021-02-08 | 2025-10-01 |
| Use of GM-CSF Treatment in Recurrent Implantation Failure GM-CSF group, CONTROL - Women With Recurrent Implantation Failure in IVF | Phase 3 | Unknown | Centre for Endocrinology and Reproductive Medicine, Italy | 140 | 2017-12-12 | 2022-07-20 |
| A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer PROSTVAC-V, PROSTVAC-F, GM-CSF - Prostate Cancer Metastatic | Phase 3 | Completed | Bavarian Nordic | 1297 | 2011-11-28 | 2019-09-04 |
| Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis - Stage IB Melanoma, Stage IIA Melanoma | Phase 3 | Withdrawn | Jonsson Comprehensive Cancer Center | 2011-08-05 | 2020-07-27 | |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Sunitinib, GM-CSF, Cyclophosphamide - Metastatic Renal Cell Carcinoma | Phase 3 | Completed | Immatics Biotechnologies GmbH | 339 | 2010-12-01 | 2017-10-12 |
| Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma Talimogene laherparepvec, GM-CSF - Melanoma | Phase 3 | Completed | BioVex Limited | 437 | 2009-04-01 | 2016-07-13 |
| Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma dactinomycin, vincristine sulfate, cyclophosphamide - Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma | Phase 3 | Completed | Children's Oncology Group | 702 | 2002-09-01 | 2013-06-17 |
| Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) GM-CSF - Acute Myeloid Leukemia | Phase 3 | Completed | Acute Leukemia French Association | 473 | 1999-03-01 | 2009-04-13 |
| Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF - Graft vs Host Disease, Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 30 | 1996-11-01 | 2007-09-24 |
| Combination Chemotherapy in Treating Children With Neuroblastoma filgrastim, sargramostim, carboplatin - Neuroblastoma | Phase 3 | Completed | Children's Oncology Group | 573 | 1988-03-01 | 2014-08-01 |
Leukemia, Myeloid, Acute (2) · Melanoma (2) · Carcinoma, Renal Cell (1) · Graft vs Host Disease (1) · Malignant mesenchymal tumor (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Pathologic Complete Response (1) · Prostatic Neoplasms (1) · Rhabdomyosarcoma (1) · Sarcoma (1)
Children's Oncology Group (2) · Acute Leukemia French Association (1) · Bavarian Nordic (1) · BioVex Limited (1) · Centre for Endocrinology and Reproductive Medicine, Italy (1) · Immatics Biotechnologies GmbH (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Nationwide Children's Hospital (1) · Sellas Life Sciences Group (1)
United States (9) · Canada (3) · France (3) · Germany (3) · Netherlands (3) · Poland (3) · United Kingdom (3) · Australia (2) · Hungary (2) · Italy (2) · Puerto Rico (2) · Russia (2) · Spain (2) · Belgium (1) · Denmark (1)
Brian Rini, MD (1) · Carola Arndt (1) · David L. Baker, MD, MBBS, FRACP, FRCPA (1) · James L. Gulley, MD (1) · Marco Sbracia, MD (1) · Philip Kantoff, MD (1) · Richard Essner (1) · Tim Eisen, MD (1)
PMID 17252021, PMID 20625116, PMID 20879880, PMID 21690555, PMID 26014293, PMID 27720136, PMID 28923101, PMID 30817251, PMID 31171039, PMID 37498156, PMID 38603649, PMID 39606837, PMID 40965804
2008 (1), R01CA120228 (1), U10CA098543 (1)